KyungDong Pharm home
Prescription Medicines

Pictomin Tab.

Product Category
diabetes medication
Active Ingredients
Pioglitazone hydrochloride, metformin hydrochloride
Appearance
A white to grayish-white, oblong, convex, film-coated tablet.
Reimbursement Code
648103990
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Pioglitazone hydrochloride (USP)----16.53mg (15mg as pioglitazone)
Metformin hydrochloride (in-house specification)---------850mg
- Additives: Magnesium stearate, Opadry White (03B28796), croscarmellose sodium, povidone

2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with non-insulin-dependent diabetes (type 2).

1. Cases where sufficient blood sugar control cannot be achieved with metformin or pioglitazone monotherapy
2. Alternative to pioglitazone and metformin combination therapy

Management of type 2 diabetes should include nutritional counseling, weight loss, and exercise when necessary. These efforts are important not only in the initial treatment of type 2 diabetes, but also in maintaining the effectiveness of drug treatment.

3. Dosage and dosage
In the treatment of patients with type 2 diabetes, the dosage of this drug should be individualized based on effectiveness and tolerability within the range of not exceeding the maximum dose of each ingredient, 30 mg of pioglitazone and 2,500 mg of metformin.
The initial dose of this drug should be based on the patient's current treatment regimen.

1. Patients whose blood sugar level is not adequately controlled with metformin and pioglitazone monotherapy:
The dose should be based on the current dose of metformin or pioglitazone. Start with one tablet of this medicine daily and adjust the dose gradually after assessing the therapeutic response.

2. Patients switching from combination therapy of pioglitazone and metformin:
Patients switching from combination therapy with pioglitazone and metformin to this drug can begin with the existing dosage of pioglitazone and metformin.

No studies have previously been conducted to examine the safety and effectiveness of switching from other oral hypoglycemic agents to this drug. Any change in type 2 diabetes treatment regimen may cause changes in glycemic control, so caution must be exercised and appropriate monitoring must be performed.

3. Patients with renal impairment: All dosage adjustments should be based on careful evaluation of renal function. In general, elderly, debilitated, and nutritionally deficient patients should not increase their dose to the maximum.

After administering this drug to a patient or when increasing the dose, patients should be carefully monitored for adverse reactions related to fluid retention.

This drug should generally be administered in divided doses with meals, which can reduce gastrointestinal side effects caused by metformin.

Sufficient time is needed to assess the adequacy of treatment response. Ideally, response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting blood glucose level (FPG). HbA1c reflects blood sugar levels over the past 2 to 3 months. In clinical use of this drug, if glycemic control as measured by FPG does not worsen, administration is recommended for an appropriate period of time (8 to 12 weeks) to assess changes in HbA1C.

4. Precautions for use
1. Warning
metformin hydrochloride
It may cause severe lactic acidosis or hypoglycemia. Cases of death due to lactic acidosis have been reported.
1) Lactic acidosis
Lactic acidosis is a rare but serious metabolic complication that occurs due to metformin accumulation during treatment. In 50% of cases it occurs, it is fatal. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may occur when there is significant tissue hypoperfusion and hypoxia and in conjunction with pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactic acid concentration (over 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. When metformin is believed to be the cause of lactic acidosis, metformin blood levels generally exceed 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving metformin (approximately 0.03 cases per 1,000 patients per year and approximately 0.015 fatal cases per 1,000 patients per year). Reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple medical and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, this drug should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so metformin is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol has the potential to affect metformin's lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while taking this drug.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood metformin concentration may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms often occur early in treatment once the patient has stabilized on a specific dose of metformin, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving metformin do not indicate impending lactic acidosis and may be due to other mechanisms, such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in specimen handling. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient taking this drug, the drug should be discontinued immediately and general supportive treatment should be administered immediately. Because metformin is dialyzable (clearance reaching 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.

pioglitazone hydrochloride
1) Thiazolidinediones, including pioglitazone, may cause or worsen congestive heart failure in some patients. After initiating treatment with this drug or increasing the dosage, patients should be carefully observed for symptoms and signs of heart failure (including excessive and rapid weight change, dyspnea, and edema). If these symptoms and signs appear, heart failure should be managed according to current standard treatment regimens. Additionally, discontinuation or reduction of the dose of this drug should be considered.
2) Patients with severe heart failure (patients with New York Heart Association (NYHA) class 3 or 4 heart conditions) should not begin treatment with this drug. Administration of this drug in patients with symptomatic heart failure is not recommended.
3) Heart failure and other actions on the heart
Pioglitazone, like other thiazolidinedione drugs, can cause fluid retention when administered alone or in combination with other anti-diabetic drugs such as insulin. Fluid retention can cause or worsen heart failure. Patients should be observed for signs or symptoms of heart failure. When these symptoms and signs occur, heart failure should be managed according to current standard treatments. Additionally, discontinuation or dose reduction of this drug should be considered.
In a 16-week, double-blind, placebo-controlled clinical trial in the United States in 566 patients with type 2 diabetes, 15 mg and 30 mg doses of pioglitazone and combination therapy with insulin were compared with insulin monotherapy. This clinical trial included patients with long-standing diabetes and the following pre-existing medical conditions with high prevalence: arterial hypertension (57.2%), peripheral neuropathy (22.6%), coronary heart disease (19.6%), retinopathy (13.1%), myocardial infarction (8.8%), vascular disease (6.4%), angina (4.4%), stroke and/or transient ischemic attack. (4.1%), and congestive heart failure (2.3%).
In this study, 2 (1.0%) of 191 patients receiving pioglitazone 15 mg plus insulin and 2 (1.1%) of 188 patients receiving pioglitazone 30 mg plus insulin developed congestive heart failure, compared with none of 187 patients on insulin alone. All four patients had a history of cardiovascular abnormalities, including coronary artery disease, previous coronary artery bypass grafting (CABG), and myocardial infarction. In a 24-week dose-adjustment trial of pioglitazone and insulin combination therapy, congestive heart failure was reported as a serious adverse reaction in 1 (0.3%) of 345 patients who received 30 mg of pioglitazone and insulin and 3 (0.9%) of 345 patients who received 45 mg of pioglitazone and insulin.
Analysis of data from this study identified no specific factors that could predict an increased risk of congestive heart failure with combination therapy with insulin.
4) Type 2 diabetes and congestive heart failure (systolic dysfunction)
A 24-week post-marketing safety study was conducted to compare pioglitazone (n=262) and glyburide (n=256) in patients with uncontrolled diabetes (average glycated hemoglobin (HbA1c) 8.8% at pre-treatment) with New York Heart Association (NYHA) class 2 or 3 cardiac status and ejection fraction less than 40% (mean ejection fraction 30% at pre-treatment). carried out. During clinical trials, hospitalization for congestive heart failure was reported in 9.9% of patients receiving pioglitazone compared to 4.7% of patients receiving glyburide, with treatment differences observed starting at week 6. These adverse reactions associated with pioglitazone were more pronounced in patients receiving insulin in the pretreatment phase and in older patients over 64 years of age. No differences in cardiovascular mortality were observed between treatment groups.
When pioglitazone is prescribed to patients with type 2 diabetes and systolic heart failure (New York Heart Association (NYHA) class 2), it should be initiated at the lowest approved dose. If subsequent dose increases are necessary, they should be increased gradually after several months of treatment with careful monitoring for signs and symptoms of weight gain, edema, or worsening congestive heart failure.
5) Prospective pioglitazone clinical trial for cases of macrovascular complications (PROactive):
In PROactive, 5238 patients with type 2 diabetes and a prior history of macrovascular disease were administered pioglitazone (n=2605) by force-titration up to 45 mg once daily or placebo (n=2633) (see Adverse Reactions). The proportion of patients who developed serious heart failure was higher in patients receiving pioglitazone (5.7%, n=149) compared to patients receiving placebo (4.1%, n=108). Following reports of serious heart failure, the incidence of death was 1.5% (n = 40) in patients receiving pioglitazone and 1.4% (n = 37) in patients receiving placebo. At baseline, the incidence of serious heart failure was 6.3% (n=54/864) in patients taking pioglitazone and insulin compared with 5.2% (n=47/896) in patients receiving placebo. The incidence of serious heart failure in patients receiving pioglitazone and sulfonylureas was 5.8% (n=94/1624) compared with 4.4% (n=71/1626) in placebo.
6) When administering to patients with a history of bladder cancer, the benefit of blood sugar control should be considered compared to the risk of cancer recurrence due to use of this drug.
7) If signs of gross hematuria or other symptoms such as dysuria or urgency appear or increase during treatment, the patient should be instructed to immediately notify the doctor, as these symptoms may be due to bladder cancer.

2. Do not administer to the following patients:
1) Patients with severe heart failure (patients with New York Heart Association (NYHA) class 3 or 4 heart conditions) should not begin treatment with this drug.
2) Patients with moderate (stage3b) and severe renal impairment (creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2). Kidney disease or renal dysfunction, which can result from conditions such as cardiovascular collapse (shock), acute myocardial infarction and sepsis (men with low serum creatinine levels)
Patients with 1.5 mg/dL or more, or 1.4 mg/dL or more for women, or abnormal creatinine clearance)
3) Patients with active bladder cancer
4) Patients with congestive heart failure requiring drug treatment
5) Patients undergoing tests that involve intravenous administration of radioiodine contrast material (e.g. intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, in patients scheduled for such tests, this drug should be discontinued at least 48 hours before administration, and renal function should be reevaluated after 48 hours and found to be normal. Treatment is resumed only after this.)
6) Patients with known hypersensitivity to this drug or its ingredients
7) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
8) Diabetic precoma
9) Patients with severe infections, severe traumatic systemic disorders, before and after surgery
10) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
11) Hepatic dysfunction (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), pulmonary infarction, patients with severe pulmonary dysfunction and other conditions prone to hypoxemia, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
12) Pregnant women, women who may be pregnant, and lactating women

3. Administer with caution to the following patients:
(There is a possibility of lactic acidosis and hypoglycemia)
1) Irregular meals, insufficient meal intake
2) Intense muscle exercise
3) Patients taking interacting drugs

4. Adverse reactions
[Pioglitazone hydrochloride/metformin hydrochloride]
More than 8500 patients with type 2 diabetes have received pioglitazone in randomized, double-blind, controlled clinical trials, including 2605 patients with type 2 diabetes and macrovascular disease who received pioglitazone in the PROactive trial. In these clinical trials, more than 6,000 patients received pioglitazone for at least 6 months, more than 4,500 patients received pioglitazone for at least 1 year, and more than 3,000 patients received pioglitazone for at least 2 years.

In a 16-week controlled clinical trial of the combination of placebo and metformin and the combination of pioglitazone 30 mg and metformin, the most common adverse reactions reported in at least 5% of patients were upper respiratory tract infection (15.6% in the placebo group, 15.5% in the combination therapy group), diarrhea (6.3% in the placebo group, 4.8% in the combination therapy group), and combined edema/peripheral edema. (2.5% in the placebo group, 6.0% in the combination therapy group) and headache (1.9% in the placebo group, 6.0% in the combination therapy group).

In a 24-week clinical trial comparing the combination of pioglitazone 30 mg with metformin and the combination of pioglitazone 45 mg with metformin, the incidence and types of adverse reactions reported in at least 5% of patients in all combination treatment groups are shown in Table 1. The incidence of adverse events leading to study discontinuation between the two treatment groups was 7.8% and 7.7%, respectively.

※ Table 1: Refer to attached document

Most clinical adverse reactions were similar in the pioglitazone/metformin combination group and the pioglitazone monotherapy group. Other adverse reactions reported in at least 5% of patients in comparative trials of pioglitazone monotherapy versus placebo included myalgia (placebo 2.7%, pioglitazone 5.4%), tooth disorders (2.3%, 5.3%), worsening diabetes (8.1%, 5.1%), and pharyngitis (0.8%, 5.1%), respectively.

In a double-blind clinical trial conducted in the United States, anemia was reported in more than 2% of patients treated with the combination of pioglitazone and metformin.

In clinical trials of pioglitazone monotherapy, edema was reported in 4.8% of pioglitazone-treated patients (dose range 7.5 mg to 45 mg) compared to 1.2% of placebo-treated patients. Most of these adverse events were considered mild or moderate in severity.

[Prospective pioglitazone clinical trial for cases of macrovascular complications (PROactive)]
In the PROactive clinical trial, 5,238 patients with type 2 diabetes with a history of macrovascular disease were randomly assigned to a test group that administered pioglitazone as an adjunct to standard therapy (N=2605), a test group that administered pioglitazone by forced titration up to a daily dose of 45 mg, or a placebo group (N=2633). Almost all patients (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II receptor blockers, potassium channel blockers, nitrate agents, diuretics, aspirin, statins, and fibrates). The average age of patients at the start of the trial was 62 years, the average duration of diabetes was 9.5 years, and the average HbA1c was 8.1%. The average follow-up period was 34.5 months.
The primary objective of this trial was to investigate the effect of pioglitazone on mortality and macrovascular morbidity in patients with type 2 diabetes who are at high risk for macrovascular complications. The primary efficacy variable was the time to the first event of any of the following cardiovascular composite endpoints, which included all-cause death, non-fatal myocardial infarction (MI), stroke, acute coronary syndrome, cardiovascular intervention including coronary artery bypass grafting (CABG) or percutaneous intervention (PCI), major lower extremity amputation above the ankle, and bypass surgery or vascular reconstruction of the lower extremity. A total of 514 (19.7%) subjects receiving pioglitazone and 572 (21.7%) receiving placebo experienced at least one event of the primary composite endpoint (risk ratio 0.90; 95% confidence interval: 0.80, 1.02; p=0.10).
There was no statistically significant difference between pioglitazone and placebo in the 3-year incidence of first events for any of these composite variables, but there was no increase in pioglitazone-related mortality or total macrovascular complications. The number of first occurrences and total number of individual cases for cases contributing to the primary composite endpoint are shown in Table 2.

※ Table 2: Refer to attached document

[Influence on clinical test values]
- Pioglitazone hydrochloride
1) Hematology: Pioglitazone can cause a decrease in hemoglobin and hematocrit. The decrease in hemoglobin and hematocrit levels with pioglitazone appears to be dose related. In placebo-controlled monotherapy clinical trials, the average hemoglobin value change in patients receiving placebo was -1% to +1%, while the average hemoglobin value decreased by 2% to 4% in patients receiving pioglitazone. These changes generally occur within the first 4 to 12 weeks of administration and remain relatively stable thereafter. These changes may be related to the increases in plasma volume associated with pioglitazone therapy and are unlikely to be associated with clinically significant hematological effects.
2) Serum transaminase levels: In all clinical trials conducted in the United States, a total of 14 (0.30%) of 4,780 patients administered pioglitazone had ALT values more than three times the upper limit of normal.
The elevation of ALT was reversible in all patients with follow-up values. In the patient population treated with pioglitazone, mean values ​​of bilirubin, AST, ALT, alkaline phosphatase, and GGT decreased at the final visit compared to baseline. Less than 0.9% of patients treated with pioglitazone were discontinued from clinical trials conducted in the United States due to abnormal liver function tests.
In pre-licensure clinical trials, there were no cases of idiosyncratic drug reactions resulting in hepatic dysfunction (see General Precautions, Hepatic Effects).
3) Creatine phosphokinase (CPK) level: In clinical trials, while serum creatine phosphokinase (CPK) was measured as specified in the clinical trial protocol, an isolated increase in CPK exceeding 10 times the upper limit of the normal range was observed in 9 subjects (0.2%) who received pioglitazone (level = 2150~11400 IU/L), and in subjects who received the control drug. Not observed. Of these patients, 6 continued to take pioglitazone, 2 had an increase in CPK on the last day of treatment, and 1 patient discontinued the test drug due to this increase. These increases resolved without notable clinical sequelae. The relationship between these reactions and pioglitazone therapy is unknown.

- Metformin hydrochloride
1) Controlled clinical trial administering metformin hydrochloride for 29 weeks
In the test, previously normal serum vitamin B12 levels decreased to below normal in approximately 7% of patients without clinical symptoms. This decrease is due to the inhibition of B12 absorption from the B12-intrinsic factor complex, but has little to do with anemia and is quickly recovered when metformin is stopped or vitamin B12 is supplemented.

[Pioglitazone hydrochloride post-marketing experience]
The following adverse reactions were identified during post-marketing use of pioglitazone. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure.
# Onset or worsening of diabetic macular edema accompanied by decreased vision
# Fatal and non-fatal liver failure
Postmarketing reports of congestive heart failure have been reported in patients receiving pioglitazone, both with and without a prior history of cardiac disease, and in patients receiving concomitant insulin with or without insulin.
In post-marketing experience, there have been reports of abnormally rapid weight gain exceeding that typically observed in clinical trials. Patients who experience this weight gain should be evaluated for fluid accumulation and volume-related events, such as excessive edema and congestive heart failure.

[Pioglitazone hydrochloride/metformin hydrochloride domestic post-marketing survey results]
① As a result of a post-marketing survey conducted on 638 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 5.49% (35/638 people, 42 cases in total) regardless of causal relationship.
Among these, the occurrence rate of serious adverse events was 0.31% (2/638 people, 2 cases), with ‘blood sugar abnormalities’ and ‘gastroenteritis’ each at 0.16% (1/638 people, 1 case). There were no serious adverse events for which a causal relationship with this drug could not be ruled out.
The occurrence rate of unexpected adverse events was reported to be 3.13% (20/638 people, 23 cases in total) regardless of causal relationship, and the main adverse events were ‘indigestion’ at 0.47% (3/638 people, 3 cases), ‘insomnia’ at 0.31% (2/638 people, 2 cases), ‘dry mouth’, ‘constipation’, ‘abdominal distension’, ‘Blood sugar abnormalities’ and ‘joint pain’ each accounted for 0.16% (1/638 people, 1 case). Among these, the occurrence rate of unexpected adverse events in which a causal relationship with this drug cannot be ruled out was 0.94% (6/638 people, 7 cases in total), with ‘indigestion’, ‘constipation’, ‘abdominal distension’, ‘gastroesophageal reflux disease’, ‘gastrointestinal air retention’, ‘increased blood creatinine’, and ‘increased blood urea’ at 0.16% (1/638 people, 1 case) each. It has been reported.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of the re-examination, the following are newly identified adverse events that were statistically significantly more reported for this drug compared to the adverse events reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
· Mental illness: insomnia
· Gastrointestinal disorders: indigestion

5. Generalism
1) Pioglitazone has a hypoglycemic effect only in the presence of insulin. Therefore, this drug should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
2) Bladder cancer: As a result of a 2-year carcinogenicity test, bladder tumors were observed in male rats. In two 3-year clinical trials of pioglitazone using placebo or glyburide as a comparator, bladder cancer was reported in 5 of 2633 patients (0.19%) who did not take pioglitazone, and in 14 of 2605 patients (0.44%) who took pioglitazone. After excluding patients who had been exposed to the test drug for less than 1 year at the time of bladder cancer diagnosis, there were 6 cases (0.23%) for pioglitazone and 2 cases (0.08%) for placebo. Patients exposed to pioclitazone were observed for 10 years after completion of the clinical trial. There was no difference in the incidence of bladder cancer between patients prescribed pioglitazone and those prescribed placebo over 13 years, including the clinical trial and follow-up period (HR=1.00; [95% CI 0.59-1.72]).
Results regarding bladder cancer risk in patients exposed to pioglitazone varied depending on the study. In a 10-year prospective cohort study, a non-significant increased risk of bladder cancer was observed for subjects exposed to pioglitazone compared with subjects not exposed to pioglitazone (HR 1.60 [95% CI 0.89 to 1.26]). In a retrospective cohort trial, there was statistical significance between pioglitazone and bladder cancer (HR: 1.63; [95% CI: 1.22-2.19]). Compared with no exposure to pioglitazone, exposure to pioglitazone treatment for more than 12 months was associated with an increased risk (HR 1.4 [95% CI 0.9 - 2.1]), and use of pioglitazone for more than 24 months reached statistical significance (HR 1.4 [95% CI 1.03 - 2.0]). Interim results for this trial showed that taking pioglitazone for more than 12 months increased the relative risk of developing bladder cancer by 40%, which equates to an absolute increase of 3 cases per 10,000 (from about 7 cases per 10,000 without pioglitazone to about 10 cases per 10,000 with pioglitazone).
Observations are inconsistent and there is insufficient data to determine the risk of bladder cancer to determine whether pioglitazone is a tumor promoting factor for bladder cancer. Therefore, this drug should not be used in patients with active bladder cancer, and when administering this drug to a patient with a previous history of bladder cancer, the benefit of blood sugar control should be considered compared to the risk of cancer recurrence due to use of this drug.
3) Hypoglycemia: Patients receiving pioglitazone concomitantly with insulin or other antidiabetic drugs (especially insulin secretagogues such as sulfonylureas) may be at risk for hypoglycemia, and a dose reduction of the concomitantly administered antidiabetic drug may be necessary to reduce the risk of hypoglycemia.
4) Cardiovascular System: In a placebo-controlled clinical trial in the United States that excluded patients with New York Heart Association (NYHA) Class 3 or 4 cardiac conditions, there was no increased incidence of serious cardiac adverse events associated with increased volume in patients treated with pioglitazone as monotherapy or in combination with a sulfonylurea or metformin versus placebo.
In an insulin combination study, a small number of patients with a history of cardiac disease developed congestive heart failure when pioglitazone was administered in combination with insulin (see WARNINGS). Pioglitazone has not been studied in patients with New York Heart Association (NYHA) Class 3 or 4 cardiac conditions in clinical trials. This drug is not indicated for the treatment of patients with New York Heart Association (NYHA) class 3 or 4 heart conditions.
During post-marketing surveillance of pioglitazone, cases of congestive heart failure were reported in both patients with known and unknown prior cardiac disease.
5) Edema: In all pioglitazone clinical trials conducted in the United States, edema was reported more frequently in pioglitazone-treated patients than in placebo-treated patients and appeared to be dose-related (see Adverse Reactions section). The onset or worsening of edema was reported in post-marketing surveillance. For patients with edema, this drug should be used with caution. Because thiazolidinedione drugs, including pioglitazone, can cause fluid retention that can cause or worsen congestive heart failure, this drug should be used with caution in patients at risk for heart failure. Patients should be monitored for signs and symptoms of heart failure (see WARNINGS).
6) Weight gain: Dose-related weight gain occurred when pioglitazone was used alone or in combination with other antidiabetic drugs. The mechanism of weight gain is unclear, but likely involves a combination of fluid retention and fat accumulation.
Weight changes for pioglitazone and placebo in the 16-26 week randomized, double-blind monotherapy trial, the 16-24 week combination therapy trial, and the PROactive trial are shown in Tables 1 and 2.

※ Tables 1 and 2: Refer to attached documents

Note: The median exposure period for both pioglitazone and placebo was 2.7 years.

7) Ovulation: Like other thiazolidinedione drugs, this drug therapy may cause ovulation in some premenopausal anovulatory women. As a result, these patients may be at increased risk of becoming pregnant while taking this medication. Therefore, appropriate contraception should be recommended to premenopausal women. Because this possible action has not been studied in clinical trials, its incidence is unknown.
8) Action on the liver:
This drug should not be administered to patients who have clinical evidence of active liver disease or elevated serum transaminase levels (2.5 times the upper limit of normal for ALT) at the time of initiation of treatment. Periodic monitoring of liver enzyme levels before and after treatment with this drug is recommended for all patients.
There have been post-marketing reports of fatal and non-fatal liver failure in patients taking pioglitazone, but these reports did not contain sufficient information to establish causality. There is no evidence of drug-induced hepatotoxicity in the controlled clinical trial data to date for pioglitazone.
People with type 2 diabetes may have heart disease with fatty liver or incidental congestive heart failure, both of which can cause abnormal liver tests and may also present with other forms of liver disease, many of which can be treated or managed. Therefore, it is recommended to evaluate patients by obtaining liver test values ​​(serum ALT, AST, alkaline phosphatase, and total bilirubin) before starting treatment with pioglitazone. In patients with abnormal liver tests, caution should be used when starting pioglitazone treatment.
Perform liver tests promptly in patients who report symptoms that may indicate liver damage, including fatigue, loss of appetite, right upper abdominal discomfort, melanuria, or jaundice. In this clinical situation, if the patient exhibits abnormal liver tests (ALT greater than 3 times the upper limit of the normal range), pioglitazone treatment should be discontinued and investigation should be conducted to determine the possible cause. Pioglitazone treatment should not be resumed in these patients unless there is another cause for the abnormal liver tests.
Patients with no other etiologies, serum ALT levels greater than 3 times the upper limit of the normal range, and serum total bilirubin levels greater than 2 times the upper limit of the normal range should not resume pioglitazone treatment due to the risk of severe drug-induced liver damage. Patients with less elevated serum ALT or bilirubin levels and for other reasons may be treated with pioglitazone with caution.
9) Macular edema
In post-marketing studies, macular edema has been reported in diabetic patients receiving pioglitazone or other thiazolidinedione drugs. Some patients presented with blurred vision or reduced vision, while others were diagnosed during routine eye exams. Most patients presented with peripheral edema at the time macular edema was diagnosed. In some patients, macular edema improved after discontinuation of thiazolidinedione drugs. Diabetic patients should undergo regular eye examinations by an ophthalmologist according to current standard treatments. Diabetics who report visual symptoms of any kind should promptly seek medical attention from an ophthalmologist, regardless of the patient's underlying medication or other physical findings.
10) Fracture
In the PROactive trial, 5238 patients with a history of type 2 diabetes and macrovascular disease were randomly assigned to pioglitazone (N=2605), forced titration of pioglitazone dose up to 45 mg/day, or placebo (N=2633) as an adjunct to standard treatment.
During a mean follow-up period of 34.5 months, the incidence of fractures in women was 5.1% (44/870) with pioglitazone compared to 2.5% (23/905) with placebo. These differences were observed after the first year of treatment and persisted throughout the trial period. Most fractures observed in female patients were nonvertebral fractures and involved the lower extremities and distal upper limbs. No increase in fracture rate was observed, with 1.7% (30/1735 people) for men and 2.1% (37/1728 people) for placebo. In post-marketing surveillance, fractures were reported in both men and women. Fracture risk should be considered in patients receiving long-term treatment with pioglitazone, and attention should be paid to assessing and maintaining bone health according to current standard treatments.
11) Monitoring of renal function: Metformin is mostly excreted by the kidneys, and the risk of metformin accumulation and lactic acidosis increases depending on the degree of renal function impairment. Therefore, patients with serum creatinine values ​​above the upper limit of normal for their age should not take this drug.
Renal function must be tested before starting treatment with this drug and at least once a year thereafter to check if it is normal. Patients with creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.732), discontinue treatment with this drug. Special caution is needed in situations that may lead to rapid renal function impairment, such as when there are symptoms of dehydration (severe or persistent vomiting or diarrhea) or when starting medications that affect renal function (such as antihypertensive drugs or diuretics and non-steroidal anti-inflammatory drugs (NSAIDS)). In these acute situations, metformin should be discontinued immediately and temporarily.
12) Co-administration of drugs that may affect renal function or the elimination of metformin: Co-administration of drugs that may affect renal function, cause significant hemodynamic changes, or inhibit the elimination of metformin, such as cationic drugs that are eliminated through renal tubular secretion, should be cautious. Metformin is a substrate of organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Since OTC inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, non-steroidal anti-inflammatory drugs (NSAIDS), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be closely monitored when administered in combination with metformin. Do it.
13) Diabetes-like symptoms: Consider application only to patients with an established diagnosis of diabetes. Be aware that in addition to diabetes, there are diseases with diabetes-like symptoms such as abnormal glucose tolerance and positive urine glucose (nephrogenic diabetes, geriatric glucose metabolism abnormalities, thyroid dysfunction, etc.).
14) Hypoxic state: Whatever the cause, cardiovascular collapse (shock), acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia are associated with lactic acidosis and can cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
15) Alcohol consumption: Alcohol is known to increase the effect of metformin on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
16) Surgery: During the surgical procedure, administration of this drug should be temporarily suspended (excluding mild procedures with no restrictions on food and fluid intake) and administered again after the patient's oral intake is restored and renal function is assessed as normal.
17) Vitamin B12 levels: In a clinical trial that lasted 29 weeks, in approximately 7% of patients receiving metformin, normal serum vitamin B12 levels were observed to decrease below normal before the test, without clinical symptoms. However, this decrease is possible because it interferes with B12 absorption from the B12-intrinsic factor complex, has little correlation with anemia, and is quickly recovered by discontinuing metformin administration or supplementing with vitamin B12. Patients receiving this drug should have their hematological values ​​checked annually, and any obvious abnormalities should be appropriately evaluated and managed. Certain individuals (those with inadequate intake or absorption of vitamin B12 or calcium) may be predisposed to having vitamin B12 values ​​below normal. In these patients, it may be useful to have regular serum vitamin B12 measurements at intervals of 2 to 3 years.
18) Changes in controlled diabetic patients: If a patient whose type 2 diabetes was previously well controlled with this drug develops abnormal laboratory findings or clinical disease (especially vague and poorly defined disease), the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar are tested, and, if necessary, blood pH, lactate, pyruvate, and metformin levels. If any form of acidosis appears, immediately stop administering this drug and take other appropriate and correct measures.
19) Hypoglycemia: Hypoglycemia does not occur in patients who take metformin alone under normal use circumstances, but occurs when caloric intake is insufficient, when vigorous exercise is not supplemented by caloric intake, or when other hypoglycemic agents (sulfonylureas, insulin, etc.) or alcohol are administered together. In particular, hypoglycemia is likely to occur in the elderly, patients with weak or nutritional imbalances, patients with adrenal or pituitary insufficiency, or alcoholics. Hypoglycemia may be difficult to identify in older adults and people taking β-adrenergic blocking drugs.
20) Failure of blood sugar control: Patients stabilized with certain diabetes treatments may temporarily fail to control blood sugar when exposed to stress such as fever, convulsions, infection, or surgery. At these times, this drug may be discontinued and temporary insulin administration may be required. This drug may be resumed after the acute crisis has resolved.
21) Patients with specific occupations: Metformin, one of the ingredients of this drug, may rarely cause severe lactic acidosis and severe delayed hypoglycemia, so be careful when administering it to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
22) Patients should be informed of the potential benefits and risks of this drug and other treatment methods. Additionally, they should be informed of the importance of maintaining a diet, regular exercise plan, regular blood sugar testing, glycated hemoglobin, renal function, and hematological values.
The risk of lactic acidosis caused by metformin, one of the ingredients of this drug, its symptoms, and possible predispositions should be explained to the patient. If unexplained hyperventilation, muscle pain, fatigue, abnormal confusion, or other unspecified symptoms occur, stop taking this medication immediately and notify your medical staff.
Advise patients about the risks of excessive alcohol consumption, whether acute or chronic, while taking this medicine.
23) Response to all diabetes treatments should be monitored by regularly measuring fasting blood sugar and glycated hemoglobin levels with the aim of lowering the levels to the normal range. Initially, fasting blood glucose can be used to determine treatment response. Therefore, both blood sugar and glycated hemoglobin should be monitored. Glycosylated hemoglobin levels are particularly useful in assessing long-term control.
24) Initial and regular monitoring of hematological values (e.g. hemoglobin/hematocrit, red blood cell index) and renal function (serum creatinine) should be performed at least once a year. Megaloblastic anemia is rarely observed during treatment with metformin, and if suspected, vitamin B12 deficiency should be ruled out.
25) If signs of gross hematuria or other symptoms such as dysuria or urgency appear or increase during treatment, the patient should be instructed to immediately notify the doctor, as these symptoms may be due to bladder cancer.
26) Macrovascular complications: There are no clinical trials establishing conclusive evidence for macrovascular risk reduction for this drug or any other antidiabetic drug.

6. Interaction
Combination therapy with pioglitazone 1000 mg and pioglitazone after administering 45 mg of pioglitazone for 7 days did not change the pharmacokinetics of metformin when administered as a single dose.

Although no studies have been conducted on the drug interactions of this drug, studies have been conducted on pioglitazone and metformin, respectively.

pioglitazone hydrochloride
1) Strong CYP2C8 inhibitor
CYP2C8 inhibitors (e.g., gemfibrozil) significantly increase the exposure (area under the serum concentration-time curve, or AUC) and half-life of pioglitazone. A dose reduction of pioglitazone may be necessary when coadministered with gemfibrozil or other strong CYP2C8 inhibitors.
2) CYP2C8 inducer
CYP2C8 inducers (e.g., rifampin) significantly reduce the exposure (AUC) of pioglitazone. Therefore, if a CYP2C8 inducer is initiated or discontinued during treatment with pioglitazone, it may be necessary to change diabetes treatment based on clinical response.
3) Drug–drug interactions

※ Tables 1 and 2: Refer to attached documents

metformin hydrochloride
1) Since the blood sugar lowering effect may be enhanced or reduced by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that enhance blood sugar lowering action
Insulin preparations, sulfonamide and sulfonylurea drugs, α-glucosidase inhibitors, anabolic steroids, guanethidine, salicylates (aspirin, etc.), β-blockers (propranolol, etc.), MAO inhibitors, angiotensin converting enzyme inhibitors
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may lead to accumulation of metformin and potentially expose patients to the risk of lactic acidosis. Metformin administration should be discontinued before or at the time of testing using iodine-labeled contrast media, and administered again at least 48 hours later and after confirmation of normal renal function.
4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin and glyburide did not change the pharmacokinetics or pharmacodynamic properties of metformin. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of a single dose of this drug in this study indicates that the clinical significance of this interaction is unclear.
5) Furosemide: A study on the drug interaction of metformin and furosemide administered as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of metformin without significant changes in the renal clearance of metformin, and increases blood Cmax by 22% and blood AUC by 15%. When co-administered with metformin, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when metformin and furosemide are coadministered chronically.
6) Nifedipine: A study on the drug interaction between metformin and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of metformin in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine promotes the absorption of metformin. Metformin does not significantly affect nifedipine.
7) Drugs that may affect metformin, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted as renal tubular secretion: In theory, cationic drugs excreted as renal tubular secretion (e.g. amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and Vancomycin) has the potential to act with metformin by competing for the normal renal tubular transport system. A study on the interaction between metformin and cimetidine observed during single and multiple administration to normal volunteers showed that the maximum plasma concentration and total blood concentration of metformin increased by 60%, and the metformin AUC in plasma and whole blood increased by 40%. There was no change in the elimination half-life when administered as a single dose. Metformin had no effect on the pharmacokinetics of cimetidine. Although such drug interactions are theoretically possible (except for cimetidine), close monitoring and dose adjustment of drugs that interact with metformin are recommended in patients receiving cationic drugs that are excreted through the proximal tubular secretory system.
8) Others: In single-dose co-administration studies in healthy volunteers, the pharmacokinetic properties of metformin and propranolol and metformin and ibuprofen were not affected by each other.
Metformin's binding to plasma proteins is negligible, so compared to sulfonylureas that bind extensively to plasma proteins, it has little interaction with drugs that bind to proteins in large quantities, such as salicylates, sulfonamides, chloramphenicol, and probenecid.

7. Administration to pregnant and lactating women
1) Administration to pregnant women
Current evidence strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital malformations and increased neonatal morbidity and mortality. Most experts therefore recommend insulin during pregnancy to keep blood glucose as close to normal as possible. This medicine must not be administered during pregnancy.
There have been no appropriate controlled studies on this drug or its ingredients in pregnant women. There have been no animal tests performed on this drug.
2) Administration to nursing mothers
There have been no trials performed with this drug. Pioglitazone and metformin are excreted into milk in lactating rats in studies conducted with each component. It is not known whether pioglitazone and/or metformin are excreted in human milk. Because many drugs are excreted in human milk, this medication is not administered to nursing mothers. If this drug is discontinued but blood sugar is not adequately controlled through diet alone, insulin therapy should be considered.

8. Administration to children
The safety and effectiveness of this drug have not been established in pediatric patients.

9. Administration to elderly people
Because elderly people may have reduced renal function, the initial and maintenance doses of this drug should be carefully selected. Additionally, monitoring of renal function is necessary to prevent metformin-related lactic acidosis.

pioglitazone hydrochloride
When three 16-26 week double-blind, placebo-controlled, monotherapy clinical trials were combined, a total of 92 patients (15.2%) who received pioglitazone were over 65 years of age, and 2 patients (0.3%) were over 75 years of age. When two 16- to 24-week clinical trials of combined administration with sulfonylurea were combined, 201 patients (18.7%) who received pioglitazone were over 65 years of age, and 19 patients (1.8%) were over 75 years of age. When two 16- to 24-week clinical trials in combination with metformin were combined, 155 (15.5%) patients who received pioglitazone were over 65 years of age, and 19 (1.9%) were over 75 years of age. When two 16- to 24-week clinical trials of combined use with insulin were combined, 272 (25.4%) patients who received pioglitazone were over 65 years of age, and 22 (2.1%) were over 75 years of age.
In the PROactive clinical trial, 1,068 (41.0%) patients who received pioglitazone were over 65 years of age, and 42 (1.6%) were over 75 years of age.
In pharmacokinetic studies of pioglitazone, no significant differences in pharmacokinetic parameters were observed between elderly and young patients. Although conclusions are limited by the small sample size of patients over 75 years of age, this clinical experience did not identify differences in safety and efficacy between older (65 years of age or older) and younger patients.

metformin hydrochloride
Although there are clinical reports that there are no differences in response between elderly and adult patients, controlled clinical trials of metformin have not obtained a sufficient number of elderly patients to determine whether they respond differently from adults. Metformin is known to be mostly excreted through the kidneys, and since there is a risk of serious drug side effects in patients with inadequate renal function, it should be used only in patients with normal renal function. Since aging is associated with a decrease in renal function, the minimum dose that achieves appropriate blood sugar control effects should be set based on the patient's renal function. Elderly people should have their renal function monitored regularly, and the maximum dose of metformin is generally not administered to elderly people.

10. Treatment in case of overdose
pioglitazone hydrochloride
During comparative clinical trials, one case of pioglitazone overdose was reported. A male patient took 120 mg/day for 4 days and 180 mg/day for the next 7 days. The patient denied any clinical symptoms during this period.
If an overdose event occurs, appropriate supportive care should be initiated according to the patient's clinical signs and symptoms.

metformin hydrochloride
Overdosage with metformin trisalt has occurred, including cases where doses exceeding 50 g were ingested. Hypoglycemia was reported in approximately 10% of all cases, but a causal relationship with metformin hydrochloride has not been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases. Metformin is dialyzed with clearance rates reaching 170 mL/min under favorable hemodynamic conditions. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing on metformin.

11. Pharmaceutical equivalence test information
In a 2 × 2 crossover study, 36 healthy adults received a single oral dose of one tablet each of the test product, Pictomin tablets (KyungDong Pharm Co., Ltd.), and the reference product, Actosmet 15/850 mg tablets (Takeda Pharmaceuticals Korea), under fasting conditions. Plasma pioglitazone and metformin concentrations were measured. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating bioequivalence.

※ Table: Refer to attached document

12. Others
pioglitazone hydrochloride
1) Carcinogenicity, mutagenicity, fertility
A two-year carcinogenicity study was conducted on male and female rats at an oral dose of up to 63 mg/kg (approximately 14 times the maximum recommended oral dose of 45 mg for humans based on mg/m2). No drug-induced tumors were found in any organ except the bladder. Benign and/and malignant cellular neoplasms have been observed in male rats receiving doses greater than 4 mg/kg/day (approximately equivalent to the maximum recommended human oral dose on a mg/m2 basis). A 2-year carcinogenicity study was conducted in male and female mice at oral doses up to 100 mg/kg/day (approximately 11 times the maximum recommended oral dose for humans based on mg/m2). No drug-induced tumors were found in any organ.
Pioglitazone hydrochloride was not shown to be mutagenic in a series of genotoxicity studies such as reverse mutation (Ames) test using bacteria, forward mutation test (CHO/HPRT and AS52/XPRT) using mammalian cells, in vitro cytogenetic analysis using CHL cells, unscheduled DNA synthesis assay, and in vivo micronucleus test.
No adverse effects on fertility were observed in male and female rats administered oral doses of up to 40 mg/kg (approximately 9 times the maximum recommended human oral dose based on mg/m2) of pioglitazone daily before and throughout mating and pregnancy.
Pioglitazone was not shown to be teratogenic at oral doses up to 80 mg/kg in rats or 160 mg/kg in rabbits during the organogenesis phase (approximately 17 and 40 times the maximum recommended human oral dose on a mg/m2 basis, respectively). Delayed parturition and embryotoxicity (as evidenced by increased postimplantation loss, delayed development, and decreased fetal body weight) have been observed in rats at oral doses above 40 mg/kg/day (approximately 10 times the maximum recommended human oral dose based on mg/m2). No functional or behavioral toxicity was observed in rat offspring. In rabbits, embryotoxicity was observed at an oral dose of 160 mg/kg (approximately 40 times the maximum recommended human oral dose based on mg/m2). Human based on 10 mg/kg (mg/m2)
Postnatal growth retardation due to weight loss has been observed in rat offspring during late pregnancy and lactation at oral doses greater than or equal to approximately 2 times the maximum recommended oral dose.
2) Animal toxicity
Cardiac hypertrophy has been observed in mice (100 mg/kg), rats (4 mg/kg or more), and dogs (3 mg/kg) administered orally with pioglitazone hydrochloride (approximately 11, 1, and 2 times the maximum recommended human oral dose based on mg/m2 in mice, rats, and dogs, respectively). In a 1-year rat study, early drug-related death due to apparent cardiac dysfunction occurred at an oral dose of 160 mg/kg/day (approximately 35 times the maximum recommended human oral dose on a mg/m2 basis). A 13-week study in monkeys showed cardiac hypertrophy at oral doses above 8.9 mg/kg/day (approximately 4 times the maximum recommended human oral dose on a mg/m2 basis), but not in a 52-week study at oral doses up to 32 mg/kg (approximately 13 times the maximum recommended human oral dose on a mg/m2 basis).
3) Two clinical trials were conducted on the combination therapy of pioglitazone and metformin. Two trials selected patients with type 2 diabetes who were receiving metformin alone or in combination with other diabetes medications. All other diabetes medications were discontinued before starting study treatment.
In the first trial, 328 patients with type 2 diabetes who were taking metformin alone or in combination with other antidiabetic drugs were randomly assigned to receive pioglitazone 30 mg or placebo once daily in addition to their metformin therapy for 16 weeks. Any other antidiabetic medications were discontinued. Compared with placebo, adding pioglitazone to metformin significantly reduced mean HbA1c by 0.83% and mean FPG by 37.7 mg/dL at 16 weeks.
In the second trial, 827 patients were randomly assigned to receive 30 mg or 45 mg of pioglitazone once daily in addition to their current metformin for 24 weeks. The mean reduction in HbA1c at week 24 from pretreatment was 0.80% and 1.01% for the 30 mg and 45 mg doses, respectively. The mean reduction from pretreatment in FPG was 38.2 mg/dL and 50.7 mg/dL.
Based on these reductions in HbA1c and fasting blood sugar, co-administration of pioglitazone with metformin showed significant improvement in glycemic control regardless of metformin dose.

metformin hydrochloride
1) Metformin is a primary or secondary regenerating drug and does not exhibit pharmacokinetic properties that cause addiction.
2) Long-term carcinogenicity tests were conducted on rats (dose lasting 104 weeks) and mice (lasting 91 weeks) at doses of 900mg/Kg/day and 1500mg/Kg/day, respectively. This dose is approximately three times the human body's maximum daily allowance based on body surface area.
There was no evidence of metformin-related carcinogenicity in either male or female mice. Similarly, there was no tumorigenic potential due to metformin in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/Kg/day.
There was no evidence for the mutagenic potential of metformin in reverse mutation assays (S. typhimurim), genetic mutation assays (mouse lymphoma cells), chromosomal aberration assays (human lymphocytes), or in vivo micronucleus assays (mouse bone marrow cells).
The fertility of male and female rats was not affected by metformin when administered at a high dose of 600 mg/Kg/day, which is approximately twice the maximum daily allowable dose based on body surface area.
3) Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day.
This represents approximately two and six times the recommended daily human dose of 2000 mg for rats and rabbits, respectively, based on body surface area. Fetal concentration measurements demonstrated that metformin partially crosses the placental wall.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
28 tablets (7 tablets/Alu-Alu

7. Period of use
36 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Pictomin Tab.Picto Minjeong (Precautions for use)2018.07.09PDFPicto Minjeong.pdf